These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 667867)

  • 1. Systolic time intervals: an effective measure of cardiac function in anthracycline-induced cardiomyopathy of rabbits.
    Long HJ
    Cancer Treat Rep; 1978 Jun; 62(6):911-4. PubMed ID: 667867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.
    Hutchinson RJ; Bailey C; Wood D; Donaldson MH
    Cancer Treat Rep; 1978 Jun; 62(6):907-10. PubMed ID: 667866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive polygraphic cardiac changes in daunorubicin-induced cardiomyopathy in rabbits.
    Gersl V; Hrdina R
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1994; 37(2):49-55. PubMed ID: 7784798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy.
    Mason JW; Bristow MR; Billingham ME; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):857-64. PubMed ID: 667859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systolic time interval recordings in rabbits with congestive cardiomyopathy induced by chronic anthracycline administration.
    Long HJ; Diamond SS; Burningham RA; Raflo CP
    Am J Vet Res; 1983 Jul; 44(7):1375-7. PubMed ID: 6576659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10.
    Cortes EP; Gupta M; Chou C; Amin VC; Folkers K
    Cancer Treat Rep; 1978 Jun; 62(6):887-91. PubMed ID: 667863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].
    Lenzhofer R; Schneeweiss B; Rameis H; Eichler H; Graninger W; Dittrich C; Dudczak R; Ganzinger U; Gasic S; Moser K
    Wien Klin Wochenschr; 1983 Jan; 95(2):52-5. PubMed ID: 6858169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline cardiomyopathy monitored by morphologic changes.
    Billingham ME; Mason JW; Bristow MR; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):865-72. PubMed ID: 667860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
    Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive profile in the prospective monitoring of adriamycin cardiomyopathy.
    Fulkerson PK; Talley R; Kleinman D; Weaver SK; Leier CV; Balcerzak SP; Lewis RP
    Cancer Treat Rep; 1978 Jun; 62(6):881-6. PubMed ID: 667862
    [No Abstract]   [Full Text] [Related]  

  • 11. Systolic time interval recordings as a measure of cardiac function in the healthy rabbit: reference values.
    Long HJ; Diamond SS; Burningham RA; Raflo CP
    Am J Vet Res; 1982 Aug; 43(8):1497-9. PubMed ID: 7103236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Noninvasive cardia fúnction diagnosis in children treated with adriamycin (author's transl)].
    Schmaltz AA; Treuner J; Class U; Heil RP
    Klin Padiatr; 1980 Nov; 192(6):502-8. PubMed ID: 7194391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systolic time intervals in monitoring adriamycin-induced cardiotoxicity.
    Balcerzak SP; Christakis J; Lewis RP; Olson HM; Malspeis L
    Cancer Treat Rep; 1978 Jun; 62(6):893-9. PubMed ID: 667864
    [No Abstract]   [Full Text] [Related]  

  • 14. The interval-force relationship: a technique for evaluating the cardiac toxicity of anthracycline analogs.
    Breed JG; Zimmerman AN; Meyler FL; Pinedo HM
    Cancer Treat Rep; 1979 May; 63(5):869-73. PubMed ID: 455328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity.
    Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ
    Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
    Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
    J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
    Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits.
    Zieba R; Wagrowska-Danilewicz M
    Pol J Pharmacol; 2003; 55(6):1079-87. PubMed ID: 14730104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
    Working PK; Newman MS; Sullivan T; Yarrington J
    J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Echocardiographic evaluation of adriamycin cardiotoxicity during polychemotherapy (author's transl)].
    Christmann D; Bareiss P; Boilletot A; Bergerat JP; Oberling F
    Nouv Rev Fr Hematol (1978); 1981; 23(3):149-54. PubMed ID: 7290990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.